| Autor: |
Jan J. Molenaar, Louis Chesler, Huib N. Caron, Rogier Versteeg, Robbert J. Kok, Rolf W. Sparidans, Kevin Petrie, Simon P. Robinson, Albert Hallsworth, Yann Jamin, Carel J.M. van Noesel, Ilona J.M. den Hartog, Marli E. Ebus, Evon Poon, M. Emmy M. Dolman |
| Rok vydání: |
2023 |
| DOI: |
10.1158/1078-0432.22454799.v1 |
| Popis: |
Supplementary figures S1-8. Fig. S1. Sensitivity of neuroblastoma cells to AT7519 is partially dependent on MYCN amplification status. Fig. S2. AT7519 more potently induces PARP cleavage in MYCN-amplified neuroblastoma cells. Fig. S3. FACS plots showing the in vitro effects of AT7519 on sub-G1 induction and the fraction of cells in G1, S and G2. Fig. S4. Effects of combination therapy with AT7519 and conventionally used drugs in neuroblastoma treatment on cell viability of IMR32. Fig. S5. AT7519 causes tumour growth inhibition in MYCN-amplified neuroblastoma xenografts after dose-dependent accumulation in the tumour. Fig. S6. AT7519 inhibits the CDK2 targets p-Rb and p-NPM in AMC711T neuroblastoma xenografts. Fig. S7. AT7519 causes tumour volume reduction in Th-MYCN transgenic mice, but tumours relapse during treatment. Fig. S8. AT7519 induces cleaved caspase 3 in Th-MYCN transgenic mice. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
